These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16373260)

  • 1. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus.
    Briani C; Zara G; Rondinone R; Iaccarino L; Ruggero S; Toffanin E; Ermani M; Ghirardello A; Zampieri S; Sarzi-Puttini P; Doria A
    Autoimmunity; 2005 Nov; 38(7):549-55. PubMed ID: 16373260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
    Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
    Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus.
    Briani C; Zara G; Rondinone R; Della Libera S; Ermani M; Ruggero S; Ghirardello A; Zampieri S; Doria A
    Neurology; 2004 Jun; 62(12):2288-90. PubMed ID: 15210897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
    Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
    Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
    Kocer B; Sucak G; Kuruoglu R; Aki Z; Haznedar R; Erdogmus NI
    Acta Neurol Belg; 2009 Jun; 109(2):120-6. PubMed ID: 19681443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus.
    Thomson KF; Goodfield MJ
    J Dermatolog Treat; 2001 Sep; 12(3):145-7. PubMed ID: 12243705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thalidomide therapy for discoid lupus erythematosus].
    Lyakhovisky A; Baum S; Shpiro D; Salomon M; Trau H
    Harefuah; 2006 Jul; 145(7):489-92, 551. PubMed ID: 16900736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
    Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
    J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case series of 48 patients treated with thalidomide.
    Doherty SD; Hsu S
    J Drugs Dermatol; 2008 Aug; 7(8):769-73. PubMed ID: 18720694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Plasmati R; Cangini D; Tacchetti P; Perrone G; Pastorelli F; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2005 Mar; 74(3):212-6. PubMed ID: 15693790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.
    Wenzel J; Brähler S; Bauer R; Bieber T; Tüting T
    Br J Dermatol; 2005 Jul; 153(1):157-62. PubMed ID: 16029342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
    Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy.
    Ordi-Ros J; Cortés F; Cucurull E; Mauri M; Buján S; Vilardell M
    J Rheumatol; 2000 Jun; 27(6):1429-33. PubMed ID: 10852265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
    Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P
    Eur J Haematol; 2004 Jun; 72(6):403-9. PubMed ID: 15128418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thalidomide and thrombosis].
    Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L
    Ann Dermatol Venereol; 2000 Feb; 127(2):171-4. PubMed ID: 10739975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.
    Maurer T; Poncelet A; Berger T
    Arch Dermatol; 2004 Jul; 140(7):845-9. PubMed ID: 15262695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide treatment for hypertrophic cutaneous lupus erythematosus.
    Gambini D; Carrera C; Passoni E; Muratori S; Berti E; Caputo R
    J Dermatolog Treat; 2004 Dec; 15(6):365-71. PubMed ID: 15764048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide and sensory neurotoxicity: a neurophysiological study.
    Zara G; Ermani M; Rondinone R; Arienti S; Doria A
    J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1258-61. PubMed ID: 18450790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thalidomide therapy of cutaneous lupus erythematosus].
    Bohmeyer J; Achenbach A; Westenberger M; Stadler R
    Hautarzt; 2002 Nov; 53(11):744-8. PubMed ID: 12402138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.